+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Drug Solubility Technology and Platforms: Evolving Strategies, Emerging Opportunities

  • ID: 1503793
  • Report
  • 110 Pages
  • Greystone Associates
1 of 2
Because drug molecules must be water soluble to be readily delivered to the cellular membrane while retaining their hydrophobic properties, issues surrounding water insolubility of active compounds have important business and market implications for new drug development. This impact extends beyond potential future drug therapeutics, affecting current reformulation strategies as well. As large-molecule therapeutics increase in number and as a percentage of all drug discoveries, the economic scales will tip in favor of those drug developers possessing the ability to engineer water-soluble formulations of inherently hydrophobic compounds. The importance of solubilization technologies is also underscored by the capability they bestow on formulators attempting to re-formulate approved drugs approaching the end of their patent life. The survey covers a dozen solubilization technologies and processes, including particle engineering, supercritical fluid processing, liposomes, modified sugars and starches, nanoparticles, and micelle structures.

- Analyzes and evaluates drug formulation processes and technologies for improving the properties of insoluble poorly soluble and/or poorly absorbed drug candidates
- Examines drug formulation issues and evolving market factors
- Provides detailed assessments and status of commercial drug formulation technology platforms designed to improve drug solubility
- Profiles drug solubility technology market participants, their research activity, proprietary technology, and business strategies
Note: Product cover images may vary from those shown
2 of 2
Executive Summary

Drug Formulation Market Dynamics
- Trends in Formulation Science
- Drug Discovery Automation
- Drug Development Productivity
- Preclinical Development Issues
- Value-added Contract Formulators
- Technology Market Drivers
- Formulation Strategies

Drug Formulation Technology Factors
- Drug Candidate Characterization
- Active Compound Stability
- Physicochemical Properties
- Drug Solubility
- Routes of Administration

Drug Solubility Technology
- Cyclodextrins
- Liposomes
- Micelles
- Microgels
- Nanosystems
- Particle Engineering
- Supercritical Fluid Processing
- Polyethylene Glycol
- Porous Microparticles
- Salt Formation
- Starch Derivatives

Drug Solubility Testing
- Standards and Testing Criteria
- Testing Technology
- Compound Screening
- Drug Solubility Test Systems
- Selected Solubility Testing Provider Profiles

Drug Solubility Technology Platform Assessments
- Biorise (Eurand)
- Biotransport (SupraTek Pharma)
- Captisol (CyDex)
- Chitosan (Archimedes)
- Cyclosert (Calando)
- Diffucaps (Eurand)
- EPAS (PharmaForm)
- EUDRAGIT (Evonik)
- FluidCrystals (Camurus)
- Formulplex (Supercritical Solutions)
- HySolv (Novartis)
- IDD (SkyePharma)
- Labrafil/Gelucire (Gattefosse)
- Lip’ral (Lipocine)
- Medusa (Flamel Technologies)
- MeltDose (Lifecycle Pharma)
- Melt Spray-Congealed Microspheres (Bend Research)
- Nanocrystals (Elan)
- NanoMorph (Soliqs)
- NovaSOL ( Aquanova)
- Novasperse (PharmaNova)
- OctoDex (OctoPlus)
- PNDS (Labopharm)
- ProRelease (Synectix)
- PVA-co-PEG (Formac)
- RubiEn (Rubicon Research)
- Solumer (SoluBest)
- Soluplus (BASF)

Market Factors

- FDA Regulations
- Clinical Trials
- Formulation Partnerships
- Protein and Peptide-based Drugs
- Dosage Forms
- Drug Delivery Technology

Company Profiles
Note: Product cover images may vary from those shown
3 of 2